Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2012 Aug 30;120(9):1916-22. doi: 10.1182/blood-2012-04-423715. Epub 2012 May 18.

Treatment of erythropoietin deficiency in mice with systemically administered siRNA.

Author information

1
Alnylam Pharmaceuticals, Cambridge, MA 02215, USA. william_kaelin@dfci.harvard.edu

Abstract

Anemia linked to a relative deficiency of renal erythropoietin production is a significant cause of morbidity and medical expenditures in the developed world. Recombinant erythropoietin is expensive and has been linked to excess cardiovascular events. Moreover, some patients become refractory to erythropoietin because of increased production of factors such as hepcidin. During fetal life, the liver, rather than the kidney, is the major source of erythropoietin. In the present study, we show that it is feasible to reactivate hepatic erythropoietin production and suppress hepcidin levels using systemically delivered siRNAs targeting the EglN prolyl hydroxylases specifically in the liver, leading to improved RBC production in models of anemia caused by either renal insufficiency or chronic inflammation with enhanced hepcidin production.

PMID:
22611156
PMCID:
PMC3433093
DOI:
10.1182/blood-2012-04-423715
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center